Get the Stockscreener App
16.06
7.11%
-1.23
Arcturus Therapeutics Holdings Inc stock is traded at $16.06, with a volume of 176.42K.
It is down -7.11% in the last 24 hours and down -22.90% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
See More
Previous Close:
$17.29
Open:
$17.18
24h Volume:
176.42K
Relative Volume:
0.43
Market Cap:
$468.34M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-13.84
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-5.36%
1M Performance:
-22.90%
6M Performance:
-14.26%
1Y Performance:
-56.94%
1-Day Range:
$16.06
$17.48
1-Week Range:
$15.34
$18.25
52-Week Range:
$14.30
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
16.06 | 468.34M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.40 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.55 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics names Moncef Slaoui as Chair Designate - MSN
State Street Corp Reduces Holdings in Arcturus Therapeutics Holdings Inc - GuruFocus.com
Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Increases By 8.6% - MarketBeat
Global mRNA Vaccines and Therapeutics Market is expected - openPR
Arcturus Therapeutics Appoints Moncef Slaoui Chair Designate -February 04, 2025 at 10:40 am EST - Marketscreener.com
Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year - MSN
Arcturus Therapeutics names Moncef Slaoui as Chair Designate By Investing.com - Investing.com UK
Vaccine Pioneer Moncef Slaoui Takes Helm at Arcturus Ahead of Critical Pipeline Milestones - StockTitan
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research - MarketBeat
Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - StockTitan
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - BioSpace
BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
ARCT (Arcturus Therapeutics Holdings) Cash-to-Debt : 8.06 (As of Sep. 2024) - GuruFocus.com
Arcturus: Downgrading As mRNA Promise Meets Market Reality (NASDAQ:ARCT) - Seeking Alpha
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews - Benzinga
BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target -January 28, 2025 at 07:27 am EST - Marketscreener.com
Leerink Partnrs Has Positive Outlook of ARCT FY2024 Earnings - Defense World
What is Leerink Partnrs' Forecast for ARCT FY2024 Earnings? - MarketBeat
Cantor Fitzgerald Forecasts ARCT FY2025 Earnings - Defense World
Q3 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World
Q3 Earnings Forecast for ARCT Issued By Leerink Partnrs - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World
Hennion & Walsh Asset Management Inc. Acquires 47,824 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Earns Buy Rating from HC Wainwright - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from HC Wainwright - MarketBeat
Arcturus Therapeutics launches Phase I Avian Influenza trials in US - Yahoo Finance
Arcturus Launches Phase 1 Trial for Next-Gen H5N1 Flu Vaccine with BARDA Funding - StockTitan
Arcturus Therapeutics Holdings Inc (ARCT) Recovers 32.52% From Low: Are We There Yet? - Stocks Register
HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 8.6%Should You Sell? - MarketBeat
Arcturus Therapeutics' SWOT analysis: sa-mRNA stock poised for growth amid challenges - Investing.com India
Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Trading 5.9% HigherWhat's Next? - MarketBeat
Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
Arcturus Therapeutics Advances Phase 2 Trials for Breakthrough CF and OTC Deficiency Treatments - StockTitan
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by Geode Capital Management LLC - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Price Target from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Increased by Franklin Resources Inc. - Defense World
Franklin Resources Inc. Acquires 36,714 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Head-To-Head Survey: Zymeworks (NYSE:ZYME) versus Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):